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Context: The co-occurrence of pheochromocytoma (PC) and renal tumorswas linked to the inherited
familial cancer syndrome vonHippel-Lindau (VHL) diseasemore than six decades ago. Subsequently,
other shared genetic causes of predisposition to renal tumors and to PC, paraganglioma (PGL), or
head and neck paraganglioma (HNPGL) have been described, but case series of non–VHL-related
cases of renal tumor and pheochromocytoma/paraganglioma tumor association syndrome
(RAPTAS) are rare.
Objective: To determine the clinical andmolecular features of non-VHL RAPTAS by literature review
and characterization of a case series.
Design: A review of the literature was performed and a retrospective study of referrals for in-
vestigation of genetic causes of RAPTAS.
Results: Literature review revealed evidence of an association, in addition to VHL disease, between
germlinemutations in SDHB, SDHC, SDHD, TMEM127, andMAX genes and RAPTAS [defined here as
the co-occurrence of tumors from both classes (PC/PGL/HNPGL and renal tumors) in the same
individual or in first-degree relatives]. In both the literature review and our case series of 22
probands with non-VHL RAPTAS, SDHB mutations were the most frequent cause of non-VHL
RAPTAS. A genetic cause was identified in 36.3% (8/22) of kindreds.
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Conclusion: Renal tumors and PC/PGL/HNPGL tumors share common molecular features and their
co-occurrence in an individual or family should prompt genetic investigations. We report a case of
MAX-associated renal cell carcinoma and confirm the role of TMEM127 mutations with renal cell
carcinoma predisposition. (J Clin Endocrinol Metab 102: 4013–4022, 2017)
Causes for the occurrence of different tumor types inthe same individual or in close relatives may include
shared environmental exposures and /or inherited neo-
plasia disorders. Combinations of specific tumor types
may strongly implicate specific inherited cancer syn-
dromes (1). Thus the combination of pheochromocytoma
(PC) and renal cell carcinoma (RCC) was recognized as a
“form fruste” of von Hippel-Lindau (VHL) disease more
than 60 years ago (2). RCC is the most common form of
adult renal cancer, and ;3% occurs from a hereditary
disorder (3). PC and paraganglioma (PGL) are functional
neuroendocrine tumors arising from the adrenal medulla
(PC) or sympathetic ganglia (PGL) with an annual in-
cidence of 2 to 8 per 1 million persons (4). The proportion
of PC/PGL cases attributable to a genetic cause is at least
10-fold higher than for RCC (5); some genetic causes of
PC/PGL also predispose to head and neck paraganglioma
(HNPGL). Nevertheless, the combination of RCC and PC/
PGL in a single individual or close relatives is rare and, if
cases of VHL disease are excluded, clinical and molecular
studies are limited mostly to anecdotal case reports (6–9).
In this study, we have investigated the genetic archi-
tecture of the clinical association (in the same individual or
family) of a renal tumor and a PC/PGL/HNPGL without
evidence of VHL disease [referred to here as non-VHL
renal and pheochromocytoma/paraganglioma tumor as-
sociation syndrome (RAPTAS)]. We undertook a com-
prehensive literature review and a retrospective study of
a large case series of 22 probands (index cases) and 11




Details of patients referred for molecular genetic testing
because of a suspected hereditary cause of PC/PGL or RCC
over a period of 15 years (2001 through 2016) were reviewed
and those with clinical (e.g., in addition to PC/RCC, the
presence of retinal or central nervous system hemangio-
blastoma, multiple renal or pancreatic cysts, pancreatic neu-
roendocrine tumors, endolymphatic sac tumors) or molecular
evidence of VHL disease were excluded. Patients included had
either (1) a personal history of PC/PGL/HNPGL and a renal
tumor or (2) the presence of PC/PGL/HNPGL andRCC in FDRs
(e.g., PC in a proband and RCC in a parent). Patients meeting
these criteria were classified as having non-VHL RAPTAS.
Referral data from three UK National Health Service molecu-
lar diagnostic laboratories undertaking genetic testing were
collated on a standardized pro forma and included sex, age at
presentation, method of presentation (sporadic vs familial),
location of tumor, presence of bilateral/multifocal disease, and
evidence of malignancy. Molecular genetic testing information
was also collected. Patients gave written informed consent to a
research ethics committee–approved research study and/or data
were collected as part of a molecular genetics service evalu-
ation study.
Molecular genetic testing of patients in case series
Some cases referred before 2011 had individual gene testing
(e.g.,VHL, SDHB) but more recent cases were tested for a panel
of up to 10 susceptibility genes (SDHA, SDHB, SDHC, SDHD,
SDHAF2, VHL, MAX, TMEM127, RET, FH), mostly using a
next-generation sequencing (NGS)-based assay described pre-
viously (10). All participants gave informed consent for clinical
diagnostic genetic testing. NGS was performed using the Illu-
mina or Ion Torrent platforms. On average, coverage depth
of.20-fold was achieved for 98% of the regions sequenced. All
pathogenic variants were confirmed by Sanger sequencing.
Copy number changes inVHL, SDHB, SDHC, and SDHDwere
sought by multiple ligation probe analysis. Targeted tumor se-
quencing was performed on DNA extracted from four macro-
dissected formalin-fixed paraffin-embedded tumor samples with a
custom panel based on the Ion AmpliSeq™Cancer Hotspot Panel
v2 with additional bespoke content (Supplemental Table 4). The
Covaris Adaptive Focused Acoustics™–based DNA extraction
and purification from formalin-fixed paraffin-embedded tissue
protocol was used and 20 ng of extracted DNA was sequenced.
Library preparationwas performedusing an adaptedAmpliseq on
MiSEquation 2 primer protocol. Sequencing was performed on
the Illumina MiSeq system.
Bioinformatics and histology review
See the Supplemental data for more information.
Literature review
A full review of the published literature on the genes reported
to predispose to PC/PGL or RCC up to December 2016 was
performed. This search was performed and included publications
indexed in PubMed (http://www.ncbi.nlm.nih.gov/pubmed) up
to June 2017. Search terms includedNF1, RET, MAX, EGLN1,
EGLN2, MSH2, KIFIB, SDHAF2,MEN1, BAP1, CDC73,
CDKN2B, FLCN, MET, PBRM1, PTEN, TSC1, TSC2, FH,
SDHA, SDHB, SDHC, SDHD, TMEM127, and VHL genes,
hereditary, renal cell carcinoma, oncocytoma, kidney cancer,
pheochromocytoma, and paraganglioma. In addition, the Hu-
man Gene Mutation Database (www.hgmd.cf.ac.uk) and the
Leiden Open Variation Database (http://www.lovd.nl/3.0/home)
were reviewed. The search results were interrogated to identify
genetic causes of RAPTAS.
MTS
We applied the previously described multiple primary tumor
score (MTS) (11) to group A.
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Statistical analysis
Statistical testswere performed using SPSS. Summary statistics
include mean and standard deviation (SD) for continuous vari-
ables and frequency and percentage for categorical variables. A
two-sample t test was applied to parametric means and a Mann-
Whitney test was applied as the nonparametric equivalent test.
Fisher’s exact test was used to calculate the statistical difference
between proportions of wild-type versus alternate allele reads.
Results
Case series demographics
Thirty-three individuals (16 males, 17 females) with
PC/PGL/HNPGL and/or a renal tumor from 22 kindreds
without clinical or molecular evidence of VHL disease
met our criteria for the diagnosis of non-VHL RAPTAS.
This cohort was subdivided into two groups: multiple
tumor patients with a combination of PC/PGL/HNPGL +
RCC (n = 12 probands; group A) and familial non-VHL
RAPTAS cases with RCC or PC/PGL/HNPGL and an
FDR with the alternative tumor type (n = 21 patients, 10
probands; group B).
Clinical features of groupA:multiple tumor non-VHL
RAPTAS cases
Twelve patients with a diagnosis of PC/PGL and a
renal tumor were identified. The clinical details are
summarized in Table 1. Seven cases had synchronous
tumors and five metachronous. Mean age at diagnosis of
first tumor was 55.3 years (SD, 19.4; range, 10 to 76
years). Four of five metachronous cases presented with
PC/PGL/HNPGL and one patient was initially diagnosed
with RCC. In most cases, a unilateral PC was present
(75%, 9/12 patients), but there were two cases (16.6%)
with HNPGL and one with an abdominal PGL. Most
renal tumors were RCC (91.7%, 11/12 patients), but a
renal oncocytoma was present in a patient without a









Disease Germline Genetic Analysis
Histology
Reviewed
1 63 (63) Unilateral renal
oncocytoma





















5 68 (68) Unilateral PC No No detectable mutation in SDHB or VHL No
Unilateral RCC
6 41 (41) Carotid body PGL No Variant of uncertain significance No
Unilateral RCC SDHD (c.34G.A p.Gly12Ser)
Tested for SDHB/C/D and VHL
7 60 (60) Unilateral RCC No No detectable mutation in SDHB or VHL No
Unilateral PC
8 10 (26) Abdominal PGL No SDHB mutation No
Unilateral RCC c.141G.A (p.TRP47*)
Tested for VHL and SDHB
9 62 (63) Unilateral PC No SDHB mutation No
Unilateral RCC c.268C.T (p.Arg90*)
Tested for SDHB, VHL
10 43 (43) Unilateral RCC No MAX mutation No
Unilateral PC c.97C.T (p. Arg33*)
Tested for SDHA, SDHB, SDHC, SDHD,
SDHAF2, TMEM127, MAX, and FH
11 53 (62) Unilateral PCC No TMEM127 mutation Yes
Unilateral RCC c.117_120delGTCT (tested for SDHA, SDHB,
SDHC, SDHD, SDHAF2, TMEM127, MAX,
and FH)
12 34 (39) Carotid body HNPGL Yes SDHB mutation Yes
Unilateral RCC (RCC) c.79C.T (P.Arg27*).
Tested for SDHB, SDHC, SDHD, and VHL
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germline mutation. One group A patient had been di-
agnosed with breast carcinoma, but no additional tumors
such as gastrointestinal stromal, thyroid, or pituitary
tumors were identified in group A or group B patients
(Tables 1 and 2).
Clinical features of group B: familial non-VHL
RAPTAS cases
Ten kindreds were identified containing two or more
FDRs with PC/PGL/HNPGL and a renal tumor. Infor-
mation including phenotype, genotype, and demographic
information was available on 10 probands (6 females, 4
males) referred for genetic testing and basic demographic/
phenotype information was available on the 11 affected
FDRs (2 females, 9 males) (Table 2). Mean age at pre-
sentation of the probands was 56.6 years (SD, 17.3;
range, 27 to 77 years) andmean age at tumor diagnosis in
11 affected FDRs was 52.3 years (SD, 16.3; range, 13 to
65 years). In eight kindreds, the proband presentedwith a
PC/PGL/HNPGL (three with a PC, three with HNPGL,
and two with abdominal PGL) and in two cases had
malignant PGLs (an HNPGL and an abdominal PGL)
(Table 2). Two probands presentedwith RCC and a renal
oncocytoma. Most probands in group B had one affected
relative, but one proband had two affected relatives (two
brothers, both with RCC).
Molecular genetics analysis of the non-VHL RAPTAS
case series
Molecular genetic analysis was performed on all 22
probands from groups A and B. All cases were tested for
germline mutations in VHL, and SDHB and 8/12 (67%)
of probands from group A and 6/10 (60%) of probands
from cohort B were also tested for mutations in SDHA,
SDHC, SDHD, SDHAF2, FH, MAX, and TMEM127.
A germline SDHB mutation (four truncating mutations
and a splice site mutation) was detected in 6/22 (27.3%)
probands (three from group A and three from group B).
Family testing was possible in two of three group B
kindreds; in both cases, the affected relative harbored the
SDHB mutation detected in the proband.
One proband was diagnosed with a variant in SDHD
(c.34G.A, p.Gly12Ser) that was not considered patho-
genic and did not prompt family screening. One proband
presenting with RCC and unilateral PC age 43 years
had a truncating mutation in the MAX gene (Table 1).
This NGS result was confirmed by Sanger sequencing.
Another proband from group A was found to have a
truncating mutation in TMEM127 (Table 1).
No statistically significant correlation was identified for
younger age at first tumor diagnosis, PGL, renal oncocy-
toma or malignant PGL, and the identification of a genetic
mutation (P . 0.05 for all associations). The mean MTS
(11) value in group A patients with a mutation was 3.6
compared with 1.8 in those without a mutation (P = 0.09).
Histology review
Archival tumor samples were available for four patients
from group A (RCC samples from probands 2,3, 11, and
12 and a PC from proband 2) and histology review and
SDHB immunostaining was performed (Figs. 1 and 2).
Tumor sequencing
Analysis of DNA extracted from the PC and RCC
tumors from case 10 with the germline mutation in the
MAX gene (c.97C.T p. Arg33*) revealed loss of het-
erozygosity (Supplemental Fig. 4), with higher reads in
the mutant allele identified in the PC [reads wild-type/
mutant: 77/151 (depth 228) and RCC (reads: 60/179,
depth 239) compared with the germline (157/157, depth












13 56 Renal oncocytoma SDHB splice site intron mutation IVS1 + 1 G.T Daughter (13) Unilateral PC
14 50 HNPGLa No detectable mutation in SDHB or VHL Father (58) Unilateral RCC
15 77 Unilateral PC No detectable mutation in SDHA, SDHB/SDHC/
SDHD,SDHAF2, MAX, TMEM127, FH, VHL
Daughter (51) Unilateral RCC
16 57 HNPGL No detectable mutation in SDHA, SDHB/SDHC/
SDHD,SDHAF2, MAX, TMEM127, FH, VHL
Brother (54) Unilateral RCC
17 57 Abdominal PGLa SDHB mutation c.166-170delCCTCA
(p.Pro56Tyrfs5X)
Brother (57) Unilateral RCC
18 67 Abdominal PGL No detectable mutation in SDHB or VHL Brother (52) Unilateral RCC
19 19 Unilateral PC No detectable mutation in SDHA, SDHB, SDHC,
SDHD,SDHAF2, MAX, TMEM127, FH, VHL
Father (65) Unilateral RCC
20 60 Unilateral RCC SDHB mutation c.380T.G (p.Ile127Ser) Brother (64) Unilateral PC
21 60 Unilateral PC No detectable mutation in SDHB or VHL 2 brothers (50,63) Unilateral RCC
22 27 Unilateral PC No detectable mutation in SDHB or VHL Father (49) Unilateral RCC
aMetastatic disease.
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314) [germline.v’s.PC P = 0.0002; germline.v’s.RCC P,
0.0001 (Fisher’s exact test)]. No additional somatic ho-
mozygous mutations were identified in other RAPTAS-
related genes (VHL, SDHA, SDHB, SDHC, SDHD, FH,
TMEM127) in either tumor from case 10 (Supplemental
Table 4).
Loss of SDHB immunostaining in the PC from case 2
prompted additional sequencing of tumor tissue from the
PC and RCC because germline testing did not reveal a
germline mutation in SDHx or VHL (Table 1). No so-
matic mutation in SDHA/SDHB/SDHC/SDHD was
identified in either tumor, but a somatic variant (not
present in the germline) inVHL (c.245G.T pArg82Leu)
was identified in the PC tumor but not the RCC from
case 2.
Literature review
Germline mutations in at least 25 different genes have
been reported to predispose to PC/PGL/HNPGL or RCC
(NF1, RET, MAX, EGLN1, EGLN2, MSH2, KIFIB,
SDHAF2,MEN1, BAP1, CDC73, CDKN2B, FLCN,
MET, PBRM1, PTEN, TSC1, TSC2, FH, SDHA, SDHB,
SDHC, SDHD, TMEM127, andVHL) (6–9, 12–14, 15).
However, with the exception of VHL disease and, to a
lesser extent, SDHB mutations (16–20), other reported
genetic causes of RAPTAS (as defined here) are rare.
A total of 21 kindreds and 39 patients were identified
from the literature with a non-VHL RAPTAS phenotype
and a germline mutation. Mean age of tumor onset was
36.1 years (17 to 61 years) [31.8 years (17 to 47 years)
for PC/PGL/HNPGL and 41.4 (19 to 61 years) years for
Figure 1. (a) The hematoxylin and eosin (H+E)-stained compact
architecture and overall histological features consistent with a clear-
cell RCC from proband 11 with a TMEM127 mutation. (b) Positive
SDHB immunostaining in the same RCC tumor from proband 11.
(c) Histological examination of a chromophobe RCC tumor from
proband 3 with no detectable germline mutation (H+E staining
3200 high-power field). There is evidence of pleomorphic nuclei
and perinuclear halos. (d) Positive SDHB immunostaining of the
chromophobe RCC tumor.
Figure 2. (a) The H+E-stained histological appearance of the SDHB-deficient RCC from proband 12. There is evidence of intracytoplasmic
vacuoles marked by the black arrow. (b) Loss of SDHB protein expression on immunostaining of the RCC tumor from proband 12 in the lower
part of the image, with SDHB staining present in the adjacent normal renal tissue visible in the upper image. (c) The histological appearances of
a renal papillary carcinoma from proband 2 (H+E staining 3200 high-power field) and (d) preserved SDHB expression on immunostaining in this
tumor. (e) A PC tumor from proband 2. (f) Negative SDHB immunostaining in the PC. The black arrow points to an area of normal adrenal tissue
with preserved SDHB protein expression.
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RCC]. The most commonly mutated gene was SDHB
(16/21 kindreds) and 44% (7/16) had a deletion (mis-
sense in 5/16 and truncating mutations in 4/16). Most
reported cases were diagnosed with an RCC. Metastatic
RCC was reported in five patients with SDHB muta-
tions, one patient with an SDHC mutation, and one
patient with an SDHD mutation. Three cases had bi-
lateral RCC and one bilateral PC. Metastatic PC/PGL/
HNPGL occurred in one patient. Renal oncocytomawas
described as part of three cases of RAPTAS (two with
an SDHB mutation and one with a MAX mutation)
(Table 3).
In addition to patients with RAPTAS, separate case
reports of PC/PGL/HNPGL or renal tumors have been
reported in association with the six genes described in
Table 3, as well as with mutations in FH (14, 21) and
SDHA (9, 22) (although no cases of coexisting PC/PGL
and RCC in the same patient had been reported in
conjunction with a mutation in FH/SDHA). Although
there are very rare cases of tuberoses sclerosis and neu-
rofibromatosis type 1 with a PC or RCC, respectively,
these do not cause diagnostic difficulties because of the
syndromic features in such cases and have not been re-
ported to cause RAPTAS (23, 24).
Discussion
A large case series and literature review demonstrated that
non-VHLRAPTAS is genetically heterogeneous. RAPTAS
may be caused by germline mutations in six genes (VHL,
SDHB, SDHC, SDHD, TMEM127, and MAX) and two
further genes, FH and SDHA, have each been reported to
predispose to both groups of tumors (PC/PGL/HNPGL
and renal tumors) and may yet be described as a cause of
RAPTAS. Also, germline mutations inMET cause familial
type 1 papillary RCC and recently MET variants have
been linked to PC/PGL susceptibility (5).
In both the literature review and case series, SDHB
mutations were the most common identified cause of
non-VHL RAPTAS. Less frequently, RAPTAS was as-
sociated with mutations in other SDHx genes and
mutations in TMEM127 and MAX. A limitation of
this case series was that all cases had not been tested
for mutations in the rarer RAPTAS genes (SDHC,
TMEM127, andMAX) and a limitation of the literature
review is probable bias against reports of RAPTAS
without an identified genetic diagnosis. Nevertheless,
we found that there is a substantial group of RAPTAS
patients without an identified germline mutation,







(Age in Years) Sex
Tumor of Relative
(Age in Years) Reference
SDHB c.3G.A (p.Met1Ille) A+B PGL (25) Bilateral RCC (25) M RCC, brother (23) 13
SDHB c.3G.A (p.Met1Ille) B No Unilateral RCC (23) M RCC, PGL, brother
(25)
13
SDHB Exon 3 deletion A HNPGL (30) Unilateral RCC (36) M 13, 33
SDHB c.166-170 del CCTCA
(p.Pro56TryfsX5)
A PGL (28) Unilateral RCC (28) M 33
SDHB C.423+1G.A B No Unilateral RCC PC, brother (44) 7, 33
SDHB Exon 1 deletion B No Unilateral RCCa (36) M RCC, brother
(25)a
39
SDHB Exon 1 deletion A+B PC Unilateral RCC (42) F PGL, sister 39
SDHB 268C.T (p.Arg90X) A+B PGL Unilateral RCC (61) M PGL, son 33
SDHB c.286G.A (p.Gly96Ser) B No Unilateral RCC (52)a F RCC, daughter 39
SDHB c.541-2A.G B No Unilateral RCC (19) F PGL, mother 39
SDHB c.689G.A (p.Arg230His) B No Unilateral RCC (52) F PGL, daughter 39
SDHB c.541-2A.G B No Unilateral RCC (50) M RCC, brothera 39
SDHB Del exon 1 A PGL (17) Unilateral renal
oncocytoma
F 39
SDHB c.170A.G (p.His57Arg) B Unilateral RCCa (28) M PGL, mothera 20
SDHB c.847-50delTCTC A+B Unilateral
RCC (26)
PGL M RCC, PGL,
brother (24)
20
SDHC c.397C.T (p.Arg133X) B No Unilateral RCC (53)a F RCC, son (40) 39
SDHC c.3G.A (p.Met1I) B HNPGL (46) Bilateral RCC (48,60) M Bilateral RCC,
mother (48,60)
40
SDHD c.239G.T (p.Leu80Arg) A+B Bilateral HNPGL
(17), PGL(28)
Unilateral RCC (45)a M HNPGL, father,
PC brother
39
TMEM127 c.308delG (p.Gly103Alafs) A PC (47) Unilateral RCC (47) F 6





Abbreviations: F, female; M, male.
aMetastatic disease.
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suggesting that further RAPTAS genes are still to be
identified.
Recently Kopershoek et al. (8) described a germline
MAX mutation (a large, complex genomic alteration
encompassing the intragenic and promoter regions of
MAX and FUT8) in a patient with renal oncocytoma,
bilateral PC, and erythrocytosis and two siblings with
bilateral PC. In this study, we report the association
of RCC with a germline MAX mutation (c.97C.T
p. Arg33*). We detected evidence of preferential loss of
the wild-type allele in both tumors (PC and RCC) similar
to previously reported cases ofMAX-related tumors PC/
PGL (25). This finding expands the phenotype associated
withMAXmutations and raises the intriguing possibility
that MAX may be a candidate gene for inherited RCC
[SDHB mutations were originally described in associa-
tion with PC/PGL/HNPGL (26), then with RAPTAS (20),
and then familial RCC-only (16) phenotypes]. Although
mutations in all RAPTAS genes are inherited in auto-
somal dominant manner, mutations inMAX and SDHD
show a parent-of-origin–dependent tumorigenesis, and
tumors occur almost exclusively following paternal
transmission of the mutation. Hence the clinical man-
agement and genetic counseling of RAPTAS kindreds
with SDHD and MAX mutations will differ from those
with mutations in other RAPTAS genes.
We describe the second reported case of a patient
with RAPTAS resulting from a mutation in TMEM127.
The first report was in a 47-year-old woman (6) with
multifocal unilateral PC and a unilateral (clear cell)
RCC (6). A germline deletion mutation in TMEM127
(c.308delG) and an additional germline variant in
SDHB (159_*184delins25) was identified in this pa-
tient, but SDHB immunohistochemistry showed pres-
ervation of SDHB expression in both tumors. Histology
of the RCC in RAPTAS patient 11 with a TMEM127
mutation demonstrated a clear-cell RCC. Although this
is the most common type of RCC, the four additional
reported cases of TMEM127-associated RCC were all
clear-cell variant RCC (27).
Role of clinical features in suggesting specific genes
In genetically heterogeneous conditions, it is helpful if
specific clinical features can guide genetic testing. Clear-
cell RCC, PC (less often PGL and rarely HNPGL), and
retinal and central nervous system hemangioblastomas
(15) (or the presence of pancreatic or renal cysts) should
prompt genetic testing for VHL mutations. The occur-
rence of HNPGL, abdominal PGL, and malignant PPGL
or the co-occurrence of wild-type gastrointestinal stromal
tumors suggests a possible SDHxmutation. Adrenal PC is
more common in VHL disease, whereas (extra-adrenal)
PGL with SDHB disease but with a secretory pattern
(predominantly noradrenergic) is similar to VHL and
SDHX and there are similar features on positron emission
tomography computed tomography with tracers such as
18-fluorodeoxyglucose (28).
Indicators of an inherited cancer predisposition syn-
drome include the occurrence of uncommon/rare tumors
in the same individual, related tumor types in close rela-
tives, early age at diagnosis, and the presence of multi-
centric disease. In patients with RCC, genetic investigation
should be considered in sporadic cases age#45 years (29).
Although the literature review identified patientswith non-
VHL RAPTAS and a germline mutation had relatively
young-onset PC/PGL/HNPGL (mean, 31.8. years; RCC,
41.4 years) in the case series, there was no clear re-
lationship between age at tumor diagnosis and presence/
absence of a mutation. Although the difference in MTS
(11) between mutation-positive and mutation-negative
cases did not reach statistical significance, further stud-
ies are required to determine MTS utility in group A
RAPTAS cases. Although RAPTAS might in some cases
arise coincidentally, we note in two SDHB mutation-
positive cases in our series (probands 9 and 18), age at
tumor diagnosis was 60 years or older. Therefore, we
would suggest that either all cases of RAPTAS should
undergo molecular investigation or the cutoff for age at
tumor diagnosis for not pursuing genetic testing should
not be ,70 years.
Role of histology in suggesting specific genes
in RAPTAS
Histopathological features may be used to prioritize
likely genetic causes of RAPTAS (15). For example, VHL
mutations are almost invariably associated with clear-cell
RCC (30), and a unique morphology consisting of solid
architecture, distinctive intracytoplasmic inclusions, and
intratumor mast cells is characteristic of SDHB-deficient
RCC (31, 32) (Fig. 2a). Immunohistochemistry is a useful
diagnostic adjunct because SDHB-deficient RCC shows
negative immunoreactivity (33) (Fig. 2b). Interestingly,
proband 2 had evidence of succinate dehydrogenase
deficiency on SDHB immunostaining of the PC (Fig. 2c),
but immunostaining showed preserved SDHB expression
in the RCC tumor. Sequencing of both the PC and RCC
tumors in case 2 revealed a somatic mutation in VHL
(c.245G.T pArg82Leu) in the PC but not the RCC, with
no evidence of mutation in SDHA/SDHB/SDHC/SDHD
genes. False-positive results using SDHB immunohisto-
chemistry (as apparently occurred in this case) have been
reported for patients with germline VHL mutations (34)
(Fig. 2d). A potential alternative explanation for the
discrepant SDHB immunohistochemistry results in case 2
is that the first hit is an undetected germlineVHLmutation
(e.g., intronic mutation, copy number alteration) and that
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the somatic VHL missense mutation in the PCC was the
“second hit.” However, the RCC histology was a
papillary (Fig. 2c), whereas renal tumors in VHL disease
are clear cell (18, 35). Nevertheless, it is important to
consider that VHL mutations can lead to false-positive
results on SDHB immunohistochemistry (34); therefore,
we recommend that those patients with RAPTAS,
without a detectable germline mutation in SDHx, but
with loss of SDHB immunoexpression on tumor studies,
undergo genetic screening for VHL mutations (Fig. 3).
Molecular pathways implicated in different genetic
causes of RAPTAS
Transcriptome profiling separates inherited PC/PGL
into two categories (5). First, the “pseudohypoxic clus-
ter” with the upregulation of hypoxia signaling path-
ways and “cluster 2” is characterized by an upregulation
of kinase signaling pathways (5). VHL, FH, or SDHx-
associated PC/PGL fall into the pseudohypoxic cluster 1
(5). SDHx and FH inactivation leads to the accumulation
of oncometabolites such as succinate and fumarate that
inhibit alpha ketoglutarate dependant dioxygenase en-
zymes, promoting stabilization of hypoxia inducible factor
complex (5) and inhibiting histone and DNA demethy-
lation enzymes, resulting in DNA hypermethylation (36).
Cluster two gene mutations (RET, NF1, TMEM127,
MAX) activate the MAPK and phosphatidylinositol
3-kinase–AKT–mTOR pathways (5). MAX is a protein
that contains a basic helix loop helix zipper commonly
involved in a complex formation and sequences in the
promoter region of hundreds of genes encoding for proteins
essential in cellular metabolism and angiogenesis (37).
Investigation of potential RAPTAS patients
In study group A patients, one-third presented with
PC/PGL/HNPGL and were subsequently diagnosed with
an RCC. The longest interval between the presenting
tumor (abdominal PGL) and diagnosis of RCC was 16
years (proband 8). For the other three patients, mean
interval between the first tumor and RCC was 4 years
(median, 2 years; range, 1 to 9 years). Recently published
European guidelines recommend a 10-year follow-up
for patients with sporadic PC and life-long follow-up
for patients with PGL/HNPGL or those patients with a
confirmed genetic predisposition. The recommendations
for follow-up include biochemical and radiological sur-
veillance that would include abdominal imaging capable
of detecting renal tumors. Data from this study suggest
that this surveillance protocol will facilitate the detection
of patients with RAPTAS (38).
Patients meeting our clinical criteria for RAPTAS
should be referred for genetic testing. If gene panel
testing is not available/undertaken, then single-gene testing
should be prioritized as suggested in Fig. 3. It is important
Figure 3. Flowchart of the recommended genetic evaluation of potential RAPTAS kindreds. MLPA, multiple ligation-dependant probe
amplification.
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that SDHB mutation analysis includes investigation for
exonic deletions/duplications because the literature review
revealed a higher than expected proportion of deletions in
SDHB-associated RAPTAS. Mutation-positive cases
should receive appropriate follow-up and surveillance.
The clinical benefits of identifying germline genetic vari-
ants in patients with non-VHL RAPTAS also include
family screening, and, in the future, genetic classification
may facilitate a personalized treatment approach.
Conclusion
We described the largest cohort to date of non-VHL
RAPTAS and have undertaken a literature review of
reported cases. The term RAPTAS (rather than inherited
PC-PC) emphasizes thatmany casesmay be sporadic with
no family history and that not all cases may have a ge-
netic origin. We provide guidelines for genetic testing in
suspected RAPTAS and for clinical diagnostic criteria
that include both sympathetic and parasympathetic
PGL (with PC) in the criteria and both malignant (RCC)
and benign (oncocytoma) renal tumors. Application of
whole-exome and whole-genome sequencing to un-
diagnosed RAPTAS cases will provide further insights
into the molecular mechanisms of this association and
improve the management of these cases.
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